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Abstract Several bone resorptive stimuli affect osteoclasts
indirectly by modulating the production and release of osteo-
blastic factors. Using electrophoretic mobility shift assays, we
found that not only tumour necrosis factor-K (TNF-K) but also
interleukin-1L and parathyroid hormone (PTH) caused dose and
time-related increases in nuclear factor UB (NF-UB)-DNA
binding in Saos-2 human osteoblastic (hOB) cells. Activation
of NF-UB by TNF-K was reproduced in primary hOBs. In
contrast, consistent with their previously reported lack of
response to steroid hormones, Saos-2 cells did not respond to
1,25-dihydroxyvitamin D3. We suggest that NF-UB activation in
osteoblastic cells constitutes an important pathway in osteoblast-
mediated resorptive signalling.
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1. Introduction
Osteoclasts are responsible for bone removal during resorp-
tion. However, their generation from haemopoietic precursors
and the rate of their activity are regulated by various immune
and haemopoietic factors produced locally from other cells
present in the bone microenvironment [1].
It is now well established that several bone resorptive stim-
uli, such as parathyroid hormone (PTH), thyroid hormone
(T3), 1,25-dihydroxyvitamin D3 (1,25-(OH)2 vitamin D3), tu-
mour necrosis factor-K (TNF-K), interleukin-1 (IL-1) and
prostaglandin (PG) E2 (PGE2), a¡ect osteoclast formation
and activity indirectly by modulating the production and/or
release of a variety of marrow stromal/osteoblastic factors.
These include (a) various cytokines and growth factors, such
as IL-1K and L, IL-6, IL-11, TNF-K, di¡erentiation inducing
factor/leukemia inhibitory factor TGF-L, M-CSF and GM-
CSF (reviewed in [2]), the membrane associated TNF-related
activation-induced cytokine (TRANCE) and its decoy recep-
tor osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor
(OCIF) [3], (b) PGs (such as PGE2, [4]) and nitric oxide (NO,
[5]), which are the products of cyclooxygenase-2 (COX-2) and
inducible NO synthase (iNOS), respectively, and (c) colla-
genase, other metalloproteinases and adhesion molecules,
such as osteopontin and VCAM-1 [2].
Among these factors, TRANCE, which is a newly discov-
ered member of the membrane-associated TNF ligand family
(also called receptor activator of nuclear factor UB (NF-UB)
(RANK) ligand, OPG ligand or osteoclast di¡erentiation fac-
tor (ODF) (reviewed in [6])), has recently been identi¢ed as
the long-sought osteoblast-derived osteoclastogenic factor
that mediates the resorptive activity of various systemic and
local stimuli via cell-to-cell contact [3,6]. By binding to its
receptor RANK on osteoclast progenitors and mature osteo-
clasts, TRANCE induces osteoclast di¡erentiation and activa-
tion via the NF-UB signal transduction pathway [6].
NF-UB is a ubiquitous transcription factor found in many
di¡erent cell types. It regulates the transcription of many
genes involved in in£ammation and, depending on the cell
type, it either prevents or promotes apoptosis (reviewed in
[7]). In its most common form, NF-UB is a heterodimer of
one p50 subunit and one p65 subunit. In unstimulated cells,
NF-UB exists in an inactive, cytosolic form, bound to its in-
hibitor IUB. Upon stimulation of cells with a large variety of
pathophysiological agents, including cytokines and reactive
oxygen intermediates (such as hydrogen peroxide), the phos-
phorylation and ubiquitin-regulated proteolysis of IUB re-
leases the active form of NF-UB, facilitating translocation of
active NF-UB into the nucleus where it binds to DNA and
controls gene expression.
There is no doubt that NF-UB activation in osteoclastic
cells plays a critical role in the di¡erentiation and activation
of these cells. However, there is also indirect evidence that
NF-UB may be involved in regulating the expression of im-
portant genes in osteoblasts. Decameric binding sites for NF-
UB have been demonstrated within the promoter regions of
genes encoding many stromal/osteoblastic factors involved in
bone resorption, such as cytokines (reviewed in [7]), as well as
COX-2 [8], iNOS [9] and matrix metalloproteinases-1 (MMP-
1; collagenase [10]) and -9 (MMP-9; gelatinase 95 kDa) [11].
Therefore, we used a human osteoblastic (hOB) cell line
(Saos-2) to screen a panel of structurally di¡erent, local and
systemic resorptive stimuli (namely TNF-K, IL-1L, PTH and
1,25-(OH)2 vitamin D3) for their ability to activate NF-UB in
hOBs. To show that any response was not a unique property
of the Saos-2 cell line, we also tested the TNF-K e¡ect on
normal hOBs derived from trabecular bone surfaces.
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2. Materials and methods
2.1. Tissue culture materials and hormones
All tissue culture materials were obtained from Gibco BRL (Pais-
ley, UK) unless otherwise stated. Tissue culture medium (TCM) was
RPMI 1640 with HEPES (25 mM), supplemented with foetal calf
serum (FCS) (10% v/v), L-glutamine (2 mM) and antibiotics penicillin
(100 IU/ml) and streptomycin (100 Wg/ml). Synthetic bovine PTH (1^
34) fragment (bPTH (1^34); National Institute of Biological Stand-
ards and Control, NIBSC, South Mimms, UK) was dissolved in 1 mM
acetic acid containing protease free 0.1% bovine serum albumin (Sig-
ma, Poole, UK). The snap-frozen aliquots of bPTH (1^34), recombi-
nant human TNF-K (rhTNF-K) and rhIL-1L (both from Boehringer-
Mannheim, East Sussex, UK) were diluted in TCM immediately prior
to addition to cultures. Ten WM stock of 1,25-(OH)2 vitamin D3 in
isopropanol:K-MEM/10% FCS (25:100; v/v) (kindly provided by Dr.
Martin Calverley, Leo Labs, UK) was serially diluted further in TCM
prior to addition to cultures. The ¢nal concentration of isopropanol
in samples with the highest 1,25-(OH)2 vitamin D3 concentration
(10 nM) was 0.00025%.
2.2. Cell cultures
Saos-2 cells (passage numbers 18 and 19) were cultured with a
seeding density of 1.5U106 cells/90 mm dish (Falcon) in TCM.
When con£uent, cells were treated with either rhTNF-K (2.5 pg/ml^
25 ng/ml) or rhIL-1L (1 pg/ml^10 ng/ml) or synthetic bPTH (1^34)
fragment (0.001^10 IU/ml) or 1,25-(OH)2 vitamin D3 (1 pM^10 nM)
or their respective vehicles for various time periods ranging from
30 min to 6 h as stated in the ¢gure legends.
Adult hOBs were obtained from trabecular bone chips of a 38 year
old male with no metabolic bone disease. The bone sample was ob-
tained during corrective orthopedic surgery. Osteoblasts, isolated and
cultured as described previously [5], were removed from dishes by
trypsinisation at con£uency (approximately 1 month later), counted
and used for experiments. With enzyme histochemistry, at least 60%
of the isolated cells were found to be positive for alkaline phospha-
tase, a marker of osteoblastic cells. For experiments, primary osteo-
blastic cells were cultured at a seeding density of 3U106 cells/90 mm
dish in TCM. At con£uency (usually 24^48 h post cell seeding), TNF-
K (10 ng/ml) was added to cultures for 1 and 4 h. Cultures were
terminated as described below and nuclear proteins were extracted
and analysed by electrophoretic mobility shift assays (EMSA).
2.3. Extraction of nuclear proteins
Cultures were terminated by washing cells (three times) in ice-cold
phosphate-bu¡ered saline and lysing them with 1 ml of RNA lysis
bu¡er (0.6% NP-40, 150 mM NaCl, 10 mM Tris pH 7.9, 1 mM
EDTA) directly in the tissue culture dish while standing on ice. Nu-
clear extracts (NE) were prepared by the method of Hoppe-Seyler et
al. [12] and the aliquots of NE were kept at 370‡C until assayed. The
concentration of protein in NE was measured using a dye binding
assay kit (Bio-Rad). By this method, a 90 mm dish of con£uent
Saos-2 cells would typically yield 25^30 Wg protein in the NE fraction.
2.4. EMSA
Ten Wg of NE was used per binding reaction (total volume of 20 Wl)
and was incubated with a 32P-labelled synthetic double-stranded oli-
C
Fig. 1. The dose-response and time-course e¡ects of TNF-K on the
activation of NF-UB in hOB cells in culture. A^C: EMSA of NE
from Saos-2 cells cultured in the absence or presence of rhTNF-K
(0.0025^25 ng/ml) for 30 min (A), 1 h (B) and 4 h (C). Lanes in A:
1: Hela nuclear protein extract (Hela NE); 2, 3, 5^7: TNF-K (ng/
ml) at 0 (control), 0.025, 0.25, 2.5, 25, respectively; 8: 100-fold ex-
cess synthetic oligonucleotide containing the AP-1 DNA binding site
incubated with NE from 25 ng/ml TNF-K. Lanes in B: 1: Hela
NE; 2^7: TNF-K (ng/ml) at 0 (control), 0.0025, 0.025, 0.25, 2.5 and
25, respectively; 8: 100-fold excess of synthetic oligonucleotide con-
taining the NF-UB DNA binding site incubated with NE from
25 ng/ml TNF-K. Lanes in C: 1^6: TNF-K (ng/ml) at 0 (control),
0.0025, 0.025, 0.25, 2.5 and 25, respectively. The dose-response rela-
tionship was reproduced in a total of eight separate experiments,
each carried out at a time point of either 30 min, 1, 2, 4 or 6 h.
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gonucleotide having the consensus sequence speci¢c for NF-UB
(Promega, Southampton, UK). Binding reactions were carried out
at room temperature and samples were electrophoresed on native
4% polyacrylamide/0.5UTBE gels as described (by Promega). Follow-
ing electrophoresis, the gels were dried under vacuum for 45 min and
exposed to ¢lms (GRI, Essex, UK) in the dark at 370‡C for time
periods between 7 h and 3 days.
As a positive control, Hela cell nuclear protein extract was used
instead of the sample. The synthetic oligonucleotide with the complete
NF-UB motif or oligonucleotide with SP-1 or AP-1 binding sites
(Promega) were incubated with the NE for 10 min prior to the addi-
tion of the labelled probe in cold competition experiments. Other
control reactions included those where the nuclear protein extracts
were omitted from the binding reactions.
3. Results
The activation of NF-UB in osteoblastic cells in response to
various resorptive stimuli was assessed by EMSA of NE pre-
pared from Saos-2 cells. EMSA detects nuclear factor binding
to a speci¢c consensus sequence on double-stranded oligonu-
cleotides. As shown in Figs. 1^3, treatment of Saos-2 cells
Fig. 2. The dose-response e¡ect of IL-1L on the activation of NF-
UB in hOB cells in culture. NE from cells cultured in the absence or
presence of rhIL-1L (0.001^10 ng/ml) for 1 h were analysed by
EMSA. Lane 1: Hela NE; lane 2: 32P-labelled probe (synthetic oli-
gonucleotide containing NF-UB binding site) without NE; lanes 3^
8: IL-1L (ng/ml) at 0 (control), 0.001, 0.01, 0.1, 1.0 and 10, respec-
tively; lane 9: 100-fold excess synthetic oligonucleotide containing
the NF-UB binding site incubated with NE from 10 ng/ml IL-1L ;
lane 10: 100-fold excess of synthetic oligonucleotide containing the
SP-1 binding site incubated with NE from 10 ng/ml IL-1L. The
dose-response relationship was reproduced in two separate experi-
ments.
C
Fig. 3. The dose-response and time-course e¡ects of PTH on the ac-
tivation of NF-UB in human Saos-2 osteoblastic cells in culture. A^
C: EMSA of NE from Saos-2 cells cultured in the absence or pres-
ence of synthetic bPTH (0.001^10 IU/ml) for 1 h (A), 2 h (B) and
4 h (C). Lanes in A^C: 1: Hela NE; 2: 32P-labelled NF-UB (syn-
thetic oligonucleotide probe) without NE; 3, 5^8: PTH at 0 (con-
trol), 0.01, 0.1, 1.0 and 10 IU/ml, respectively; 9: 100-fold excess of
unlabelled synthetic oligonucleotide containing the NF-UB binding
site; 10: 100-fold excess of unlabelled synthetic oligonucleotide con-
taining the SP-1 binding site. The dose-response relationship was re-
produced in a total of ¢ve separate experiments, each carried out at
a time point of either 1, 2 or 4 h.
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with either rhTNF-K (0.025^25 ng/ml; Fig. 1A^C) or rhIL-1L
(0.01^10 ng/ml; Fig. 2) or synthetic bPTH (1^34) fragment
(0.01^10 IU/ml; Fig. 3A^C) resulted in time and dose-related
increases in NF-UB-DNA binding. Competition experiments
revealed the DNA binding to be speci¢c for the NF-UB, since
complexes were e¡ectively competed o¡ by excess of unla-
belled NF-UB consensus oligonucleotide (Fig. 1B, lane 8)
but not by non-competitive oligonucleotides containing bind-
ing sites for unrelated nuclear factors, such as AP-1 (Fig. 1A,
lane 8) or SP-1 (Fig. 2, lane 10).
Activation of NF-UB was readily observed at the pro-re-
sorptive concentrations of both cytokines, TNF-K, IL-1L,
and PTH. NF-UB activation in response to TNF-K treatment
was observed within 30 min of treatment (the shortest time
examined) (Fig. 1A). It persisted for up to 6 h (the longest
time tested), at which time slight reductions in NF-UB-DNA
binding were detected (results not shown). Compared with
untreated cultures, there was no visible change in the mor-
phology of the TNF-K-treated cells, as examined by phase
contrast light microscopy. This suggested that TNF-K was
not cytotoxic to the cells at any of the concentrations tested.
As shown in Fig. 2, the IL-1L-induced NF-UB activation was
detectable at 0.01 ng/ml. The response to IL-1L was observed
within 1 h (the shortest time examined) and persisted for over
4 h (the longest time tested, results not shown). Similar ob-
servations were made for PTH (Fig. 3A^C).
In contrast, 1,25-(OH)2 vitamin D3 (1 pM^10 nM) pro-
duced no e¡ect on NF-UB activation at any time period
studied (1^4 h; Fig. 4). This is consistent with the previously
reported lack of e¡ect of steroid hormones, including 1,25-
(OH)2 vitamin D3, on Saos-2 cells [13].
In order to demonstrate that activation of NF-UB was not
unique to the transformed nature of the Saos-2 osteosarcoma-
derived osteoblastic cells, we tested the e¡ect of TNF-K on
primary cultures of trabecular bone surface-derived normal
hOBs. Fig. 5 shows a time-dependent activation of NF-UB
in normal hOBs treated with 10 ng/ml TNF-K for 1 and 4
h. In both the Saos-2 and primary hOB cell systems, TNF-K
caused activation of NF-UB at similar doses and time periods
(compare Fig. 1B,C to Fig. 5). We noted that, in contrast to
primary hOBs, the unstimulated Saos-2 cells had detectable
levels of activated NF-UB. Despite this background, we ob-
tained dose and time-related responses from this cell line.
4. Discussion
In this study, we looked at NF-UB activation in osteoblasts
by examining NF-UB-DNA binding in the NE obtained from
Saos-2 cells and in normal hOB cells after they were treated
with various resorptive agents. The tested range of concentra-
tions represented those which induce bone resorption in vitro
in murine and rat test systems (there are no human organ
culture models of resorption).
We found that TNF-K, IL-1L and PTH, three structurally
unrelated bone resorptive agents, activated NF-UB in hOBs.
Although it is well recognised that TNF, IL-1 and PTH act
through di¡erent receptors and intracellular signalling path-
ways, our results suggest that the activation of NF-UB in
Fig. 4. The dose-response e¡ect of 1,25-(OH)2 vitamin D3 on the
activation of NF-UB in hOB cells in culture. NE from Saos-2 cells
cultured in the absence or presence of 1,25-(OH)2 vitamin D3
(0.001^10 nM) for 1 h were analysed by EMSA. Lane 1: Hela NE;
lane 2: 32P-labelled NF-UB (synthetic oligonucleotide probe) without
NE; lanes 3^8: 1,25-dihydroxyvitamin D3 at 0 (control), 0.001,
0.01, 0.1, 1.0 and 10 nM, respectively; lane 9: 100-fold excess of un-
labelled synthetic oligonucleotide containing the NF-UB binding
site; lane 10: 100-fold excess of unlabelled synthetic oligonucleotide
containing the SP-1 binding site. The absence of a dose-response re-
lationship was reproduced in a total of four separate experiments,
each carried out at a time point of either 1, 2 or 4 h.
Fig. 5. The time-course e¡ect of rhTNF-K on the activation of NF-
UB in trabecular bone surface-derived hOB cells in culture. NE
from cells cultured in a single experiment in the absence or presence
of rhTNF-K (10 ng/ml) for 1 and 4 h were analysed by EMSA.
Lane 1: Hela NE; lane 2: 32P-labelled probe (synthetic oligonucleo-
tide containing NF-UB site) without NE; lanes 3 and 5: 0 TNF-K
(controls for 1 and 4 h TNF-K treatments, respectively); lanes 4
and 6: TNF-K at 10 ng/ml cultured for 1 and 4 h, respectively.
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osteoblasts could be one common pathway for the activation
of genes that will signal to osteoclasts, leading to resorption of
bone. Of particular signi¢cance is our ¢nding for PTH, which
is known to bind to a single receptor on the osteoblast and
exert its biological action via dual signal transduction path-
ways (reviewed in [14]), involving protein kinase A and pro-
tein kinase C. Short time-course (5 min^1 h) experiments will
help to determine whether NF-UB activation is a primary
event in the PTH signal transduction pathway.
The removal of the thin layer of osteoid from the bone
surface by means of a collagenase-dependent process is
thought to be crucial for osteoclast attachment and initiation
of osteoclastic bone resorption [15]. The osteoblast mediation
of PTH-induced resorptive activity is thought to involve sev-
eral mechanisms. One of these is the up-regulation of collage-
nase (MMP-1) [16], the transcription of which may be regu-
lated directly by NF-UB binding to its consensus sequence on
the gene [10]. It is also noteworthy that an AP-1 binding site is
present within the promoter of the collagenase gene [17]. Since
an interaction between NF-UB and AP-1 may result in en-
hancement of the AP-1 response element function [18], it is
possible that the PTH e¡ect on the collagenase gene may also
be via this interaction. PTH is also known to induce cytokine
synthesis by the osteoblast [19,20].
Both IL-1 and TNF-K stimulate bone resorption and inhibit
bone formation and they have been implicated in the patho-
genesis of osteoporosis [2]. Using a mouse osteoblastic cell
line, Kitajima et al. [21] have recently linked the induction
of NF-UB activation by high levels of TNF-K (exceeding
100 U/ml) with the apoptosis of these cells. The authors sug-
gested that this mechanism may explain bone thinning due to
inhibition of bone formation seen in severe bone in£amma-
tion. In the present study, however, the activation of NF-UB
in hOB cells occurred at much lower concentrations of TNF-K
than those required to induce apoptosis.
Several studies have demonstrated that IL-1 and TNF-K
induce both COX-2 and iNOS in osteoblasts, with the release
of PGs and NO, respectively ([22] and references therein).
Lader and Flanagan [23] have reported that PGs are essential
for human osteoclast formation under most conditions. Fur-
thermore, formation of human osteoclasts in vitro, stimulated
by IL-1K and TNF-K, is mediated by PGE2, which causes
osteoclast di¡erentiation via its e¡ect on late osteoclast pre-
cursors [23]. PGE2 was also found to stimulate the expression
of messenger RNA for TRANCE in osteoblastic cells [3].
Recently, Chambers and co-workers [24] have shown that
PGE2 synergises with TRANCE to induce osteoclastic di¡er-
entiation from haemopoietic precursors. There is evidence
from murine osteoblastic cells that NF-UB is involved in the
induction of COX-2 gene expression by TNF-K [25]. NF-UB
also plays a role in the expression of the iNOS gene [9]. Fur-
thermore, an interaction between COX-2 and iNOS pathways
in murine osteoblastic cells has been reported [22]. IL-6 and
intercellular adhesion protein-1 (ICAM-1) are also among the
TNF-induced genes shown to be directly activated by NF-UB
in rat osteoblastic cells (ROS17/2.8) [26]. Future work will
identify which other ‘bone resorptive genes’ are directly acti-
vated by NF-UB in response to the above mentioned agents in
hOBs, especially in primary cells.
Bax et al. [27] ¢rst reported that addition of hydrogen per-
oxide to the bone slice assay caused an increase in bone re-
sorption by isolated osteoclasts and discussed the possible
involvement of NF-UB in osteoclast activation. Thus, several
recent studies into the role of NF-UB in bone resorption have
focused on the activation of NF-UB in osteoclasts [28^30].
These included the demonstration that the targetted disrup-
tion of both p50 and p52 NF-UB subunits in mice resulted in
osteopetrosis [29,30]. However, although the osteoclast plays a
crucial role in the resorptive process, its generation and activ-
ity is controlled by cells of the osteoblastic lineage via the
factors which they produce in response to bone resorption
stimulators.
We suggest that, in addition to the proposed roles of NF-
UB in the osteoclast, the activation of NF-UB in the osteoblast
may also play an important role in bone resorption. This
hypothesis is supported by (i) the results of our present study
in which we show that three structurally unrelated bone re-
sorptive agents, TNF-K, IL-1L and PTH, activate NF-UB in
hOBs, (ii) recent observations in p50, p52 double gene knock-
out mice [29,30], in which the osteopetrotic phenotype was
only partially rescued by bone marrow transplantation. This
indicated that an additional contribution of the bone marrow
microenvironment, especially of osteoblasts, could not be
ruled out and (iii) the information discussed earlier that
NF-UB is involved in the regulation of genes involved in
bone cell signalling.
The activation of NF-UB is a multi-step process involving
the generation of reactive oxygen intermediates, together with
the phosphorylation, ubiquitination and proteolytic degrada-
tion of IUB. Speci¢c inhibitors of each of these steps are
available and new drugs targeted at NF-UB activation path-
ways are under development [31]. Such drugs could be useful
in the treatment of pathological bone loss.
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